{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:54:56Z","timestamp":1791248096570,"version":"4.1.0"},"reference-count":42,"publisher":"American Association of Zoo Veterinarians","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Zoo and Wildlife Medicine"],"published-print":{"date-parts":[[2024,9,5]]},"abstract":"<jats:p>Orangutan respiratory disease syndrome (ORDS) is a disease unique to orangutans (Pongo sp), characterized by chronic bacterial infection and inflammation of any region or combination of regions of the respiratory tract, including the sinuses, air sacs, cranial bones, airways, and lung parenchyma. Aggressive early intervention during a first episode may prevent progression to chronic disease. However, in the setting of an established chronic disease, intermittent acute exacerbations are associated with worsening symptoms and increased infection and inflammation. ORDS is ultimately fatal due to loss of respiratory function resulting from chronic structural damage. Utilizing potentially lifelong medications to slow the progression of chronic, destructive inflammation in the respiratory tract, chronic treatment is aimed at stabilizing the animals' respiratory function, decreasing the frequency of recurrent exacerbations, and improving their general well-being. Three adult male Bornean orangutans (Pongo pygmaeus) housed at an orangutan rehabilitation and reintroduction center in Indonesia have long histories of recurrent respiratory disease. Each underwent CT scans confirming ORDS with chronic airway disease prior to initiation of a long-term treatment protocol. Based on data-driven medical management of bronchiectasis in humans, the three orangutans have been treated with long-term combination regimens of oral azithromycin, nebulized salbutamol, and nebulized hypertonic saline. Follow-up CT scans in all three animals at least 1 yr following treatment initiation showed improvements throughout their respiratory tracts. The duration of each exacerbation period decreased, and the orangutans have longer symptom-free periods compared to before the start of treatment. At an average of 5 yr into the long-term treatment protocol, all three orangutans are thriving. Chronic medical management of ORDS modeled after human treatment of bronchiectasis has been efficacious in these three orangutans and encourages further study of this approach.<\/jats:p>","DOI":"10.1638\/2023-0142","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T05:54:11Z","timestamp":1725515651000},"page":"769-779","source":"Crossref","is-referenced-by-count":1,"title":["CLINICAL MANAGEMENT OF CHRONIC ORANGUTAN RESPIRATORY DISEASE SYNDROME IN THREE ADULT MALE BORNEAN ORANGUTANS (PONGO PYGMAEUS)"],"prefix":"10.1638","volume":"55","author":[{"given":"Fransiska","family":"Sulistyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy P.","family":"Lung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes P.","family":"Sriningsih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1213","reference":[{"key":"36","doi-asserted-by":"crossref","unstructured":"E Stringer, C Cossaboon, S Han, et al.  \"J Zoo Wildl Med.\"  47, \"Sinusitis, bronchiectasis, and flatus in a Sumatran orangutan (Pongo abelii): could this be cystic fibrosis?\" 347 (2016)","DOI":"10.1638\/2015-0058.1"},{"key":"42","doi-asserted-by":"crossref","unstructured":"N Zimmermann, M Pirovino, R Zingg, et al.  \"J Med Primatol.\"  40, \"Upper respiratory tract disease in captive orangutans (Pongo sp.): prevalence in 20 European zoos and predisposing factors.\" 365 (2011)","DOI":"10.1111\/j.1600-0684.2011.00490.x"},{"key":"1","doi-asserted-by":"crossref","unstructured":"SD Aaron, KL Vandemheen, W Ferris, et al.  \"Lancet.\"  366, \"Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.\" 463 (2005)","DOI":"10.1016\/S0140-6736(05)67060-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"RK Aronson, AP Sriningsih, F Sulistyo, et al.  \"J Zoo Wildl Med.\"  52, \"Use of computed tomography (CT) to determine the sensitivity of clinical signs as a diagnostic tool for respiratory disease in Bornean orangutans (Pongo pygmaeus).\" 470 (2021)","DOI":"10.1638\/2020-0128"},{"key":"6","doi-asserted-by":"crossref","unstructured":"RC Cambre, HL Wilson, TR Spraker, et al.  \"J Am Vet Med Assoc.\"  177, \"Fatal airsacculitis and pneumonia, with abortion, in an orangutan.\" 822 (1980)","DOI":"10.2460\/javma.1980.177.09.822"},{"key":"20","doi-asserted-by":"crossref","unstructured":"B Lawson, R Garriga, BM Galdikas,  \"J Med Primatol.\"  35, \"Airsacculitis in fourteen juvenile southern Bornean orangutans (Pongo pygmaeus wurmbii).\" 149 (2006)","DOI":"10.1111\/j.1600-0684.2006.00153.x"},{"key":"23","unstructured":"NP Lung, AS Pratamiutami, H Steinmetz, et al.  \"Proc Am Assoc Zoo Vet.\"  \"Collaboration across institutions and across continents facilitates advancements in the diagnosis and management of chronic respiratory disease of orangutans (Pongo spp.).\" 100 (2018)"},{"key":"27","doi-asserted-by":"crossref","unstructured":"MJ Parnham, VE Haber, EJ Giamarellos-Bourboulis, et al.  \"Pharmacol Ther.\"  143, \"Azithromycin: mechanisms of action and their relevance for clinical applications\" 225 (2014)","DOI":"10.1016\/j.pharmthera.2014.03.003"},{"key":"32","doi-asserted-by":"crossref","unstructured":"L Saiman, M Anstead, N Mayer-Hamblett, et al.  \"JAMA.\"  303, \"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.\" 1707 (2010)","DOI":"10.1001\/jama.2010.563"},{"key":"34","unstructured":"J Smith, N Lung, L Perkins,  \"Proc Am Assoc Zoo Vet.\"  \"The current state of orangutan health in North America and the orangutan SSP's plans for moving forward.\" 171 (2012)"},{"key":"2","doi-asserted-by":"crossref","unstructured":"J Altenburg, CS de Graaff, Y Stienstra, et al.  \"J Amer Med Assoc.\"  309, \"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non\u2013cystic fibrosis bronchiectasis: the BAT randomized controlled trial.\" 1251 (2013)","DOI":"10.1001\/jama.2013.1937"},{"key":"3","doi-asserted-by":"crossref","unstructured":"GA Anwar, SC Bourke, G Afolabi, et al.  \"Resp Med.\"  102, \"Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis.\" 1494 (2008)","DOI":"10.1016\/j.rmed.2008.06.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"GL Banes, ED Fountain, A Karklus, et al.  \"BMC Genomics.\"  21, \"Genomic targets for high-resolution inference of kinship, ancestry and disease susceptibility in orang-utans (genus: Pongo).\" 873 (2020)","DOI":"10.1186\/s12864-020-07278-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Y-T Chang, C-Y Lin, Y-H Chen, et al.  \"Front Microbiol.\"  \"Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.\" (2015)","DOI":"10.3389\/fmicb.2015.00893"},{"key":"8","doi-asserted-by":"crossref","unstructured":"JD Cogen, F Onchiri, J Emerson, et al.  \"Annals Amer Thorac Soc.\"  15, \"Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.\" 702 (2018)","DOI":"10.1513\/AnnalsATS.201801-012OC"},{"key":"9","doi-asserted-by":"crossref","unstructured":"AA Cymbala, LC Edmonds, MA Bauer, et al.  \"Treat in Resp Med.\"  4, \"The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis.\" 117 (2005)","DOI":"10.2165\/00151829-200504020-00005"},{"key":"10","doi-asserted-by":"crossref","unstructured":"M David, I Benlala, S Bui, et al.  \"J Magn Reson Imaging.\"  \"Longitudinal evaluation of bronchial changes in cystic fibrosis patients undergoing Elexacaftor\/Tezacaftor\/Ivacaftor therapy using lung MRI with ultrashort echo-times.\" 2023","DOI":"10.1002\/jmri.29041"},{"key":"11","unstructured":"S. Dharmalingam,  \"J Med Medical Sci.\"  3, \"Respiratory tract infection in infant orangutan (Pongo pygmaeus) at Orang Utan Island, Bukit Merah.\" 5 (2016)"},{"key":"12","doi-asserted-by":"crossref","unstructured":"SH Donaldson, WD Bennett, KL Zeman, et al.  \"N Engl J Med.\"  354, \"Mucus clearance and lung function in cystic fibrosis with hypertonic saline.\" 241 (2006)","DOI":"10.1056\/NEJMoa043891"},{"key":"13","doi-asserted-by":"crossref","unstructured":"KM Eastham, AJ Fall, L Mitchell, et al.  \"Thorax.\"  59, \"The need to redefine non-cystic fibrosis bronchiectasis in childhood.\" 324 (2004)","DOI":"10.1136\/thx.2003.011577"},{"key":"14","doi-asserted-by":"crossref","unstructured":"M Eichinger, CP Heussel, HU Kauczor, et al.  \"J Mag Res Imaging.\"  32, \"Computed tomography (CT) is the current \u201cgold standard\u201d for assessment of lung morphology and is so far the most reliable imaging modality for monitoring cystic fibrosis (CF) lung disease.\" 1370 (2010)","DOI":"10.1002\/jmri.22374"},{"key":"15","doi-asserted-by":"crossref","unstructured":"MR Elkins, M Robinson, BR Rose, et al.  \"N Engl J Med.\"  354, \"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.\" 229 (2006)","DOI":"10.1056\/NEJMoa043900"},{"key":"16","doi-asserted-by":"crossref","unstructured":"LC Fan, HW Lu, P Wei, et al.  \"BMC Infec Dis.\"  \"Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials.\" (2015)","DOI":"10.1186\/s12879-015-0872-5"},{"key":"17","unstructured":"MK. Fox,  \"Respiratory Disease in the North American Captive Orangutan Population.\"  (2017)"},{"key":"18","doi-asserted-by":"crossref","unstructured":"EA Gaillard, H Carty, D Heaf, et al.  \"J Radiol.\"  47, \"Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs.\" 215 (2003)","DOI":"10.1016\/S0720-048X(02)00122-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"C Kelly, JD Chalmers, I Crossingham, et al.  \"Cochrane Database Syst. Rev.\"  3, \"Macrolide antibiotics for bronchiectasis.\" CD012406 (2018)","DOI":"10.1002\/14651858.CD012406.pub2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"W Li, Z Qin, J Gao, et al.  \"Chron Respir Dis.\"  \"Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: a systematic review and adjusted indirect treatment comparison.\" (2019)","DOI":"10.1177\/1479972318790269"},{"key":"22","unstructured":"LJ Lowenstein, R McManamon, C Bonar, et al.  \"Proc Am Assoc of Zoo Vet.\"  \"Preliminary results of a survey of United States and Canadian Orangutan Mortality in the North American SSP Population from 1980 to March, 2008.\" 40 (2008)"},{"key":"24","doi-asserted-by":"crossref","unstructured":"NP Lung  and JL. Taylor-Cousar  \"Zoo and Wild Animal Medicine.\"  10, \"Chapter 99. Orangutan Respiratory Disease Syndrome.\" 685 (2022)","DOI":"10.1016\/B978-0-323-82852-9.00099-X"},{"key":"25","unstructured":"R McManamon, RB Swenson, JL Orkin, et al.  \"Proc. Am. Assoc. Zoo Vet.\"  \"Update on diagnostic and therapeutic approaches to airsacculitis in orangutans.\" 219 (1994)"},{"key":"26","doi-asserted-by":"crossref","unstructured":"PJ Mogayzel, ET Naureckas, KA Robinson, et al.  \"Am J Respir Crit Care Med.\"  187, \"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.\" 680 (2013)","DOI":"10.1164\/rccm.201207-1160OE"},{"key":"28","doi-asserted-by":"crossref","unstructured":"J Phillipa  and R. Dench  \"Fowler's Zoo and Wild Animal Medicine, Volume 9, Current Therapy.\"  \"Infectious diseases of orangutans in their home ranges and in zoos.\" 565 (2019)","DOI":"10.1016\/B978-0-323-55228-8.00080-1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"E Polverino, PC Goeminne, MJ McDonnell, et al.  \"Eur Respir J.\"  \"European Respiratory Society guidelines for the management of adult bronchiectasis.\" (2017)","DOI":"10.1183\/13993003.00629-2017"},{"key":"30","unstructured":"F Ratjen, SD Davis, S Stanojevic, et al.  \"Lancet Respir Med.\"  7, \"Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.\" 802 (2019)"},{"key":"31","doi-asserted-by":"crossref","unstructured":"DM Rodman, JM Polis, SL Heltshe, et al.  \"Am J Crit Care Med.\"  171, \"Late diagnosis defines a unique population of long-term survivors of cystic fibrosis.\" 621 (2005)","DOI":"10.1164\/rccm.200403-404OC"},{"key":"33","doi-asserted-by":"crossref","unstructured":"L Saiman, BC Marshall, N Mayer-Hamblett, et al.  \"J Amer Med Assoc.\"  290, \"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.\" 1749 (2003)","DOI":"10.1001\/jama.290.13.1749"},{"key":"35","doi-asserted-by":"crossref","unstructured":"AP Sriningsih, NP Lung, F Sulistyo, et al.  \"J Zoo Wildl Med.\"  52, \"Evaluating the efficacy of human bronchiectasis-based antibiotic therapy in the treatment of orangutan respiratory disease.\" 1205 (2021)","DOI":"10.1638\/2020-0049"},{"key":"37","doi-asserted-by":"crossref","unstructured":"JL Taylor-Cousar, TA Evans, GR Cutting, et al.  \"Am J Primatol.\"  83, \"Potentially lethal cystic fibrosis gene variant in the orangutan.\" e23097 (2021)","DOI":"10.1002\/ajp.23097"},{"key":"38","doi-asserted-by":"crossref","unstructured":"D Wang, W Fu, J Dai,  \"Medicine.\"  98, \"Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis.\" e15285 (2019)","DOI":"10.1097\/MD.0000000000015285"},{"key":"39","unstructured":"UM Weinreich, AK Alstrup, M Frost, et al.  \"Ugeskr Laeger.\"  176, \"[Recurrent periods of respiratory tract infections in a 22-year-old].\" V65601 (2014)"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Q Wu, W Shen, H Cheng, et al.  \"Respirol.\"  19, \"Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.\" 321 (2014)","DOI":"10.1111\/resp.12233"},{"key":"41","doi-asserted-by":"crossref","unstructured":"R Ziebach, B Pietsch-Breitfeld, M Bichler, et al.  \"Pediatr Pulmonol.\"  31, \"Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: Double-blind, placebo-controlled crossover study in cystic fibrosis.\" 431 (2001)","DOI":"10.1002\/ppul.1071"}],"container-title":["Journal of Zoo and Wildlife Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:18:16Z","timestamp":1791245896000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/journal-of-zoo-and-wildlife-medicine\/volume-55\/issue-3\/2023-0142\/CLINICAL-MANAGEMENT-OF-CHRONIC-ORANGUTAN-RESPIRATORY-DISEASE-SYNDROME-IN-THREE\/10.1638\/2023-0142.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1638\/2023-0142","relation":{},"ISSN":["1042-7260","1937-2825"],"issn-type":[{"value":"1042-7260","type":"print"},{"value":"1937-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}